According to Molavi et al., silybin treatment of breast cancer cells resistant to doxorubicin/paclitaxel, sensitized cells to chemotherapeutic agents by suppressing the key oncogenic pathways STAT3, AKT and ERK [46]. This evidence concerns the gene AKT1 and breast cancer.